Glatiramer Acetate Reduces Risk of Cardiovascular Disease and Myocardial Infarction
Despite rare adverse cardiovascular side-effects and given its established safety profile, GA shows promise as a novel treatment option for heart disease. Further studies could lead to an important new use of GA especially in patients who do not receive tissue plasminogen activator within the first few hours following an MI.
Authors
- Peter H. Rheinstein (ORCID: https://orcid.org/0000-0002-4608-1665)
- Steven P. Lehrer (ORCID: https://orcid.org/0000-0002-4850-094X)
Institutions
- Severn Trent (United Kingdom) (GB)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- In Vivo
- Published
- 2025-06-27
- DOI
- https://doi.org/10.21873/invivo.14001
- Primary Topic
- Cardiac Imaging and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Georgia Clinical and Translational Science Alliance
- National Center for Advancing Translational Sciences